Moxen

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Moxen

Property Description
Active ingredient Meloxicam
Form Tablet, Capsule, Solution for Injection
Pharmacological class Nonsteroidal Anti-Inflammatory Drug (NSAID)
General purpose Symptomatic relief of pain, swelling, and fever
Origin Synthetic

Classification and Identity

Moxen is a pharmaceutical product defined by its active component, Meloxicam, and its classification as a Nonsteroidal Anti-Inflammatory Drug (NSAID). This medicine belongs to the oxicam chemical subclass. As a synthetic, single-ingredient product, Moxen is manufactured via chemical synthesis and is designed for systemic action. The drug is a selective inhibitor of the cyclooxygenase-2 (COX-2) enzyme. The selective mechanism of Meloxicam is clinically recognized for its role in modulating the enzymes responsible for generating inflammatory mediators, positioning it as a key option for managing chronic inflammatory discomfort.


Active Ingredient and Available Forms

The therapeutic effectiveness of Moxen relies entirely on its core active ingredient, Meloxicam [INN]. The drug is presented in several common dosage forms, including oral preparations such as tablets and capsules, as well as a solution for intravenous injection. The availability of both oral and injectable forms allows for flexible systemic administration of the agent, distinguishing its utility in clinical practice. Meloxicam is utilized to manage inflammation and pain, easing discomfort caused by the body's persistent inflammatory response.


Core Therapeutic Purpose

The overall therapeutic purpose of Moxen stems directly from its NSAID classification. Its function is to provide generalized symptomatic relief by reducing the principal signs of inflammation, which include pain, swelling, and fever. By influencing the body's inflammatory pathways, Moxen offers a focused, systemic method for managing discomfort. Its efficacy in moderating the physical manifestations of inflammation serves as a fundamental benefit for those experiencing inflammatory symptoms.

Regulatory References

  1. EMA Meloxicam Public Assessment Report

What side effects are possible with Moxen?

Possible side effects and safety information

The safety profile of Moxen (Meloxicam), an NSAID, is defined by regulatory agencies across categories of adverse reactions, the most serious of which are highlighted in official documents.

Serious Adverse Reactions

The most significant risks documented by regulatory authorities involve two major systems. The label notes the potential for serious cardiovascular thrombotic events, such as myocardial infarction (heart attack) and stroke, which may be fatal. This risk may increase with the duration of use. Furthermore, there is an established risk for serious gastrointestinal adverse events, including bleeding, ulceration, and perforation of the stomach or intestines, which can occur at any time during treatment without warning symptoms.

Serious, rare hypersensitivity reactions, including Stevens-Johnson Syndrome (SJS), Toxic Epidermal Necrolysis (TEN), and liver damage, are also officially reported.


Frequency and System-Organ Classes

Adverse events are formally grouped by the system they affect and their frequency:

  • Common Reactions (ge 1/100 to <1/10): These frequently involve the Gastrointestinal Disorders (e.g., diarrhea, dyspepsia, abdominal pain) and Nervous System Disorders (e.g., headache, dizziness). Fluid retention (edema) is also a common observation.
  • Uncommon to Rare Reactions: Less frequent effects are documented across various systems, including Blood and Lymphatic System Disorders (e.g., anemia), Cardiovascular Disorders (e.g., hypertension, palpitations), and the potential for renal (kidney) or hepatic (liver) toxicity.

Population-Specific Safety Notes

The official safety information includes specific constraints for certain populations. Older adults are cited as having a greater risk for serious gastrointestinal adverse events. For pregnant patients, use is generally avoided from 30 weeks gestation onward due to potential risks to the fetus. The medicine is also officially contraindicated for treating pain in the setting of coronary artery bypass graft (CABG) surgery and requires caution in individuals with pre-existing severe renal or hepatic impairment.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documents define the clinical manifestations of Moxen (Meloxicam) over-ingestion, which typically present as an exacerbation of documented adverse effects. Initial manifestations include nausea, vomiting, epigastric pain, drowsiness, and lack of energy. Overdose can escalate to severe, life-threatening outcomes, necessitating immediate emergency action.

Serious Manifestations and Required Actions

The severity classification includes risks of gastrointestinal bleeding, indicated by blood in vomit or stools, along with potential central nervous system effects such as seizures, difficulty breathing, and coma. Cardiovascular collapse is also a documented severe outcome. The regulatory guidance mandates that individuals must seek immediate medical attention upon suspected overdose. Furthermore, emergency services (911) must be called immediately if the person has collapsed, is experiencing a seizure, has trouble breathing, or cannot be awakened.

Management and Monitoring

Management of over-ingestion requires symptomatic and supportive treatment because no specific antidote is known for Meloxicam toxicity. Procedural steps detailed in official labeling may include the administration of activated charcoal or gastric lavage shortly after ingestion to reduce systemic absorption. The agent Cholestyramine is specified as a measure to enhance the elimination of the drug from the body. Monitoring of vital organ function is essential following over-ingestion.

Therapeutic Uses of Moxen

Moxen (Meloxicam) is applied across several therapeutic domains to provide essential symptomatic support, focusing on relieving discomfort caused by inflammation. The medication is commonly used to help with symptoms related to inflammatory or irritative states. It generally helps to ease the overall symptom burden, contributing to improved day-to-day comfort during difficult episodes.


Therapeutic Uses and Symptom Relief

Moxen is relevant in contexts marked by increased discomfort or tension, supporting symptomatic relief for conditions such as Osteoarthritis (OA), Rheumatoid Arthritis (RA), and Ankylosing Spondylitis. It is also applicable for symptomatic relief of Juvenile Idiopathic Arthritis (JIA) in pediatric patients. The medication assists with managing symptom clusters that interfere with daily comfort, such as persistent joint pain, associated stiffness, and localized swelling.

The medication is commonly used in acute clinical scenarios, often during phases when symptoms become more noticeable, such as painful, intensified acute flare-ups or as supportive relief for moderate-to-severe post-operative pain.

“Moxen is relevant in clinical settings that involve certain distressing symptoms, including symptomatic relief for conditions where functional stability becomes affected.”

This provides supportive relief that contributes to easing the overall symptom load during symptomatic periods.

Quick Fact: Symptomatic Relief The medication is commonly used for managing symptoms related to physical discomfort and inflammatory states associated with chronic joint conditions.

Eligibility and Restrictions for Use

Who Can and Cannot Use Moxen?

Moxen (Meloxicam) eligibility is defined by official regulatory criteria, focusing on age limits, existing comorbidities, and specific physiological states.

Approved Populations and Restrictions

The medicine is approved for adults for symptomatic relief of conditions like Osteoarthritis, Rheumatoid Arthritis, and Ankylosing Spondylitis. Pediatric use is strictly limited to treating Juvenile Idiopathic Arthritis (JIA) in patients two years of age and older. Use is not recommended in children under two years, as safety has not been established. Older adults (ge 65 years) must use the medicine with greater caution due to documented increased susceptibility to gastrointestinal and renal adverse effects.


Absolute Contraindications

Moxen is contraindicated and must not be used in patients with known hypersensitivity to meloxicam, aspirin, or other NSAIDs. Use is also prohibited in individuals with active gastrointestinal ulceration or bleeding, severe, uncontrolled heart failure (NYHA Class IV), or severe, non-dialyzed liver or kidney failure. Further absolute prohibition applies during the third trimester of pregnancy and after coronary artery bypass graft (CABG) surgery.


Conditional Eligibility

Specific restrictions apply to patients on hemodialysis, requiring a maximum dose limit of 7.5 mg per day. Use is not recommended for women who are breastfeeding.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section describes interactions of Moxen (Meloxicam) that are formally documented in government regulatory sources, focusing on documented risk classifications and exposure-modifying effects.


Documented Interaction Patterns

The co-administration of Moxen with certain medicinal products results in specific documented interaction types:

  • Additive Bleeding Risk: Concurrent use with other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), high-dose Aspirin, Oral Anticoagulants (like Warfarin), Antiplatelet Agents, and SSRIs is documented to increase the risk of bleeding complications.
  • Altered Clearance and Exposure: Moxen has been shown to increase the plasma concentrations of Lithium and Methotrexate by reducing their clearance. Inhibitors of the CYP2C9 and CYP3A4 enzymes, such as Fluconazole, may increase Meloxicam plasma levels.
  • Renal Function Constraints: Co-administration with Diuretics, ACE-Inhibitors, or ARBs may reduce the antihypertensive or diuretic effects of these agents and increases the risk of acute renal dysfunction, particularly in elderly or volume-depleted populations.
  • Substance Restrictions: Ingestion of Alcohol is documented to increase the risk of gastrointestinal bleeding. Corticosteroids also increase the risk of ulceration.

Regulatory documents classify the combination with other NSAIDs as contraindicated due to the severe risk of gastrointestinal adverse events. The interaction profile establishes constraints related to both pharmacokinetic changes (drug exposure) and pharmacodynamic effects (additive risks).

Mechanism of Action

️ How Moxen Works: Mechanism of Action

Moxen's biological action is defined by the modulation of a single enzyme system that initiates inflammatory signaling. The drug's influence extends from the molecular level to central and peripheral physiological pathways.


Selective Targeting of the COX-2 Enzyme System

Moxen exerts its primary effect by acting as a selective inhibitor of the Cyclooxygenase-2 ( COX-2) enzyme. This mechanism targets a key molecular step: the conversion of Arachidonic Acid into signaling molecules called Prostaglandins. This action occurs in pathways where COX-2 upregulation is induced by inflammation, establishing it as a control point for mediator synthesis.


Modulation of the Prostaglandin Synthesis Cascade

The inhibition of COX-2 modifies early molecular steps that shape systemic physiological outcomes by substantially reducing the synthesis of pro-inflammatory Prostaglandins (such as PGE2). This leads to an alteration in signaling within targeted pathways and affects systems where these specific lipid mediators dominate. The resulting physiological consequence is a reduction in the chemical messengers that propagate tissue and central signaling.


Attenuation of Nociception and Thermoregulation

The drug engages mechanisms that influence feedback regulation within nociceptive and thermoregulatory pathways. By lowering the concentration of PGE2, Moxen reduces the intensity of nociceptive signaling in the periphery and modifies the elevated temperature set-point in the hypothalamus. This leads to physiological adjustments that define the agent's overall effect profile.

Dosage and Administration Information

Moxen is administered systemically via either the oral route (as tablets, capsules, or suspension) or by intravenous (IV) injection. The primary dosing principle requires utilizing the lowest effective dosage for the shortest duration necessary for symptomatic relief.

The standard administration schedule is once daily for all approved forms. For adult use, the typical oral starting dose is 7.5 mg, which may be adjusted upward to 15 mg once daily if a higher level of relief is required. The maximum recommended daily oral dose is strictly limited to 15 mg. The IV solution is administered by a healthcare provider as a single 30 mg daily dose, requiring the patient to be well hydrated prior to injection over a 15-second bolus.

Population Dosing Rule Maximum Daily Dose
Standard Adult Oral Start 7.5 mg, adjust up to 15 mg 15 mg
Hemodialysis Patients Dose reduction is required 7.5 mg
Pediatric (JIA) Based on body weight (0.125 mg/kg) 7.5 mg

Oral forms, which should be swallowed with water, may generally be taken without regard to the timing of meals. Different oral formulations are not interchangeable at the same milligram strength. If an oral dose is missed, patients should resume the regular once-daily schedule the following day and should not attempt to compensate by taking a double dose. Long-term use protocols for chronic conditions mandate that the necessity of treatment be periodically re-evaluated.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Moxen (Meloxicam)


Evidence for Use in Osteoarthritis (OA)

Studies exploring the symptomatic management of Osteoarthritis have been conducted for Moxen. Research explored how symptoms change over time by conducting randomized controlled trials (RCTs), where patients were typically observed for periods ranging from a few weeks up to 12 weeks. These studies included adult patients whose condition was characterized by functional limitations, often involving the knee or hip joint. Outcomes related to physical discomfort were a key focus, with researchers measuring patient-reported outcomes describing perceived discomfort, joint stiffness, and their ability to perform daily activities using standardized scales.

Findings describe patterns observed in the studies related to measurements of pain and physical function when compared to patients receiving an inactive substance (placebo). The evidence describes symptom patterns during these defined short time intervals. However, follow-up durations were limited in the primary clinical evaluation studies, meaning there is limited information for long-term outcomes related to sustained symptomatic measurement beyond several months.


Evidence for Use in Rheumatoid Arthritis (RA)

Research explored the evaluation of Moxen in adult patients with Rheumatoid Arthritis (RA), some of whom were receiving standard disease-modifying therapies. The evidence base includes RCTs and long-term open-label studies where researchers monitored measurements linked to inflammatory or irritative states. Studies examined measures of disease activity using specialized composite scores, such as the American College of Rheumatology (ACR) response criteria, as well as tracking joint counts and morning stiffness.

Research highlights measurements related to standardized criteria for RA response during the study period. Trials reported data on how symptoms were measured in the observed populations. It is important to understand that research evaluated symptom intensity and discomfort; studies exploring this drug's effect on disease modification or preventing joint damage were not the focus of these particular trials.


Research Gaps and Areas of Uncertainty

For all indications, long-term outcomes are not fully established, particularly concerning the measurement patterns of symptomatic relief over multiple years. The overall sample size in the pediatric research (Juvenile Idiopathic Arthritis) is modest, which means the data available for this population are more limited than for adult indications. Comparative evidence against certain other anti-inflammatory treatments is limited in the current scientific literature, meaning the evidence base varies across studies when considering all therapeutic options.

Frequently Asked Questions (FAQ)

Common questions about Moxen (FAQ)


Q: Is it common to feel tired after taking Moxen?

Official product information reports that effects on the central nervous system, such as dizziness and drowsiness, are potential side effects. While not common, these are recognized adverse effects that may be experienced by some patients.


Q: How does Moxen affect the liver or kidneys?

Regulatory documents indicate the potential for serious adverse reactions involving the liver (hepatic) and kidneys (renal), known as toxicity. Due to these documented risks, certain patient groups are noted to require increased caution and monitoring.


Q: Can Moxen affect my sleep patterns?

Trouble sleeping, or insomnia, is listed in official product information as a possible side effect of Moxen. Changes to sleep patterns are reported as a recognized effect in adverse event documentation.


Q: Is Moxen ever used for something other than its main approved use?

The official regulatory agencies that govern medicines define and approve Moxen only for specific therapeutic indications, such as symptomatic relief of conditions like Osteoarthritis and Rheumatoid Arthritis. The official regulatory label defines the drug’s use according to only those approved conditions.


Q: Is Moxen known to cause weight gain or weight loss?

Official documentation notes that fluid retention, or edema, is a common side effect of the medicine. Additionally, changes in body weight (both increases and decreases) are listed in the official adverse event reports.


Q: Are there any foods or drinks I should avoid while on Moxen?

Official documentation explicitly states that co-administration with alcohol is associated with an increased risk of serious gastrointestinal bleeding. This specific substance restriction is noted in official documentation.


Q: Can people with high blood pressure take Moxen?

Regulatory documents note that non-steroidal anti-inflammatory drugs (NSAIDs) like Moxen can potentially cause new or worsening high blood pressure. They may also affect how well blood pressure medications work.


Q: Is Moxen safe for older adults (seniors)?

Regulatory documents state that older adults are classified as being at a greater risk for serious gastrointestinal and renal adverse events compared to younger adults. Official documentation includes the requirement for increased caution and observation in this population.


Q: Is Moxen a new drug, or has it been used for a long time?

The tablet form of the drug was initially approved by the U.S. Food and Drug Administration (FDA) in April 2000, indicating that the drug has been available for use for a long period.


Q: Is Moxen known to affect mood or cause anxiety?

Official product information reports mood disturbance, anxiety, and nervousness as possible, though uncommon, effects on the nervous system or psychological state.


Q: How long can a person safely stay on Moxen?

The official administration protocol for managing long-term, chronic conditions requires that the necessity of treatment must be periodically reviewed and re-evaluated.


Q: Does Moxen have a 'black box warning' from the FDA?

Yes, the official FDA drug label contains a Boxed Warning. The Boxed Warning is an important communication regarding the potential for serious health events, specifically serious cardiovascular thrombotic events (like heart attack and stroke) and severe gastrointestinal adverse events (like bleeding and ulceration).


Q: What's the typical duration of the effect after taking Moxen?

The drug's presence in the bloodstream is described by its plasma elimination half-life, which is documented in regulatory sources as approximately 20 hours.


Q: What is the half-life of Moxen?

The plasma elimination half-life is a scientific measurement indicating the time required for the drug concentration in the body to be reduced by half. For Moxen, this value is approximately 20 hours, as reported in regulatory documents.


Q: Is Moxen available in different forms (e.g., pill, liquid)?

Moxen is officially presented in several systemic dosage forms, including oral tablets and capsules. It is also available as a solution for intravenous injection.


Q: Can Moxen cause changes to my skin or hair?

Official warnings document the potential for rare but serious skin reactions, such as Stevens-Johnson Syndrome (SJS). Additionally, reports of hair loss are noted within the drug's adverse event profile.


Q: Is Moxen safe for people who drive or operate heavy machinery?

Official patient information contains a cautionary statement regarding driving or operating heavy machinery. This precaution is noted because side effects like dizziness, drowsiness, or visual disturbances may occur.


Q: Do you feel side effects right away when you start taking Moxen?

The official Boxed Warning notes that serious gastrointestinal adverse events, such as bleeding or ulceration, can occur at any time during treatment. These serious events may happen with or without warning symptoms.


Q: If I miss a dose of Moxen, what is the general guidance?

According to official prescribing information, if a dose is missed, the regular once-daily schedule should be resumed the following day. It is specified that a double dose should not be taken to make up for the missed dose.


Q: Do I need to take Moxen at the same time every day?

The administration protocol for Moxen in all approved forms is specified as a once-daily schedule.


Q: Why is Moxen not recommended for people under 18?

Regulatory documents state that general pediatric use is not recommended because the drug’s safety and effectiveness have not been established in children under two years of age. Its use is strictly limited to treating Juvenile Idiopathic Arthritis (JIA) in patients aged two years and older.


Q: Can Moxen be taken with common over-the-counter pain relievers?

Regulatory documents warn that co-administration with other non-steroidal anti-inflammatory drugs (NSAIDs) is defined in regulatory documents as contraindicated. This is because combining these medicines significantly increases the risk of serious gastrointestinal adverse events.

How should Moxen be stored and disposed of?

How to Store and Dispose of Moxen (Meloxicam)

Storage and disposal of Moxen must strictly comply with official regulatory labeling to ensure product quality and public safety.


Official Storage Requirements

Moxen tablets must be stored at controlled room temperature, specifically between 20 C and 25 C (68 F and 77 F). The medicine must be kept in its original container and sealed tightly closed to protect it from moisture. Liquid forms (suspension, injection) should not be frozen. All forms of Moxen must be kept out of the sight and reach of children.


Disposal Instructions

Unused or expired Moxen must be discarded according to local pharmaceutical waste requirements. Do not dispose of this medicine via wastewater or household trash. Patients should utilize authorized drug take-back programs or follow instructions provided by a pharmacist for safe disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Moxen found in:

A-Z Index: